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Cisplatin is an anticancer agent marred by nephrotoxicity;
however, limiting this adverse effect may allow the use of
higher doses to improve its efficacy. Cilastatin, a small
molecule inhibitor of renal dehydropeptidase I, prevents
proximal tubular cells from undergoing cisplatin-induced
apoptosis in vitro. Here, we explored the in vivo relevance of
these findings and the specificity of protection for kidney
cells in cisplatin-treated rats. Cisplatin increased serum blood
urea nitrogen and creatinine levels, and the fractional
excretion of sodium. Cisplatin decreased the glomerular
filtration rate, promoted histological renal injury and the
expression of many pro-apoptotic proteins in the renal
cortex, increased the Bax/Bcl2 ratio, and oxidative stress in
kidney tissue and urine. All these features were decreased by
cilastatin, which preserved renal function but did not modify
the pharmacokinetics of cisplatin area under the curve. The
cisplatin-induced death of cervical, colon, breast, and
bladder-derived cancer cell lines was not prevented by
cilastatin. Thus, cilastatin has the potential to prevent
cisplatin nephrotoxicity without compromising its anticancer
efficacy.
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Cisplatin is a potent and reliable chemotherapeutic agent
against solid tumors.1,2 However, cisplatin time- and dose-
dependent nephrotoxicity restricts the use of high doses to
maximize the therapeutic efficacy. In fact, 25–35% of patients
develop evidence of nephrotoxicity following a single dose of
cisplatin.3 Once cisplatin enters the cell, it is bioactivated by
hydrolytic reactions. The chloride ligands are replaced by
water molecules, transforming platinum (Pt) into mono- and
di-aquadiammineplatinum (II) species. Aqua species are
more reactive than the neutral molecule and react with DNA,
creating intra-strand DNA–cisplatin cross-linking that
causes cytotoxic lesions in tumors and other dividing
cells.4 Although nonproliferating cells are relatively well
protected, proximal tubule cells are an exception, as they
are damaged by cisplatin. Therefore, finding an effective
way to prevent cisplatin-induced nephrotoxicity has become
a priority.
The mechanisms of tubular cell injury have been studied to
develop nephroprotective approaches.5,6 Several pathways of
apoptosis—extrinsic, mediated by death receptors, and
intrinsic (or mitochondrial) pathways—have been implicated
in cisplatin-induced nephrotoxicity.6 Cisplatin increases levels
of proapoptotic proteins (Bax), decreases anti-apoptotic
proteins (Bcl-2), and activates initiator and executioner
caspases.3,6–8 Oxidative stress (OS) also has a critical role in
the pathogenesis of cisplatin-induced nephrotoxicity. Reactive
oxygen species (ROS)–induced cell death has been reported in
renal proximal tubular epithelial cells (RPTECs),5,6,9 and ROS
promote cisplatin-induced renal failure.10,11 ROS directly
damage cell components, including lipids, proteins, and
DNA, and activate the mitochondrial pathway of apoptosis,
thus highlighting the interactions between both processes.5,12
Many studies have assessed the effect of various substances
to neutralize cisplatin-induced apoptosis and OS in experi-
mental nephrotoxicity.11–16 However, in some cases, the effect
or ig ina l a r t i c l e http://www.kidney-international.org
& 2012 International Society of Nephrology
Received 6 July 2011; revised 7 February 2012; accepted 6 March 2012;
published online 20 June 2012
Correspondence: Alberto Tejedor, Renal Physiopathology Laboratory,
Department of Nephrology, Hospital General Universitario Gregorio
Maran˜o´n, C/Dr. Esquerdo 46, 28007 Madrid, Spain.
E-mail: atejedor@senefro.org
7These authors contributed equally to this work. The order of authors is
arbitrary.
652 Kidney International (2012) 82, 652–663
on the tumoricidal efficacy of cisplatin is unclear, while in
others, it declined in proportion to the grade of nephropro-
tection showing that OS and apoptosis also have a prominent
role in the tumoricidal capacity of cisplatin.5,6
We have previously published the ability of cilastatin to
inhibit apoptosis induced by a large set of well-known
nephrotoxics.17–19 This property seems to be linked to the
interference of the cilastatin–dehydropeptidase I (cilastatin-
DHP-I) complex with the signaling of the extrinsic pathway
of apoptosis.17,18 We showed that cilastatin was able to inhibit
cilastatin-induced apoptosis but not necrosis in RPTECs,
reducing cisplatin–DNA binding, DNA fragmentation, mi-
tochondrial damage, and cell death. However, no changes
in the chromatographic profile of Pt-biomolecules were
observed.17
We explore the potential usefulness of cilastatin as a
nephroprotective agent in an animal model of cisplatin-
induced nephrotoxicity. Our results may have important
relevance for preservation of renal function in cancer
patients.
RESULTS
Effect of cilastatin on cisplatin-induced body weight loss
Body weight was not significantly different in rats before the
beginning of the treatment. Cisplatin reduced body weight
gain compared with the control animals. Cilastatin signifi-
cantly prevented, but did not normalize, cisplatin-induced
weight loss (Table 1). Cilastatin alone did not modify body
weight.
Cilastatin protects from cisplatin-induced renal injury
Cisplatin increased serum blood urea nitrogen and creatinine
levels, fractional excretion of sodium and water and
decreased the glomerular filtration rate in comparison with
the controls at day 5 (Table 2). Cilastatin significantly
partially or totally prevented these changes in cisplatin-
treated animals. Urinary volume and protein excretion also
increased in the cisplatin group but were significantly
reduced by cilastatin (Table 2). Cilastatin alone had no effect
on these parameters compared with the control group
(Table 2).
Cilastatin ameliorates cisplatin-induced morphological renal
damage
The toxic effect of cisplatin was also confirmed by the
detection of morphologic abnormalities in kidney slices.
Histology results for the control rats were normal (Figure 1).
The cisplatin group exhibited acute structural damage
characterized by tubular necrosis, swelling and tubular
dilation, extensive epithelial vacuolization, and hyaline casts
in renal tubules (Figure 1). The semiquantitative histological
injury score was significantly higher in cisplatin-treated rats
than in controls. Cilastatin alone had no effect on renal
morphology but reduced the renal injury score in cisplatin-
treated rats (Figure 1i).
Cilastatin reduces cisplatin-induced apoptosis
In situ detection of apoptosis. Apoptosis in the kidney was
assessed using the terminal deoxynucleotidyl transferase
(TdT)-mediated dUTP nick end labeling assay. Cisplatin
increased the number of apoptotic nuclei compared with the
control group (Figure 2). Cilastatin significantly decreased
the number of terminal deoxynucleotidyl transferase-
mediated dUTP nick end labeling-positive cells.
Expression of caspase-3 and -9. Procaspase-3 levels were
high in the renal cortex of rats treated with cisplatin,
although they were reduced by cilastatin (Figure 3f and g).
Renal sections from the cisplatin-treated group also displayed
increased activated cleaved caspase-3 staining in renal tubules
compared with untreated kidneys and kidneys treated with
cilastatin only (Figure 3a–d). Cilastatin significantly lowered
the elevated caspase-3 levels in cisplatin-injected rats, as
Table 1 | Effect of cilastatin on body weight in cisplatin-
treated rats
Groups Initial weight (g) Final weight (g) D Weight (g)
Control 264±3 279±2 15±1
Control+cil 259±8 273±7 14±2
Cisplatin 272±4 249±5 23±3a
Cisplatin+cil 272±5 259±3 13±4a,b
Abbreviation: cil, cilastatin.
aPo0.0001 vs. control and control+cil.
bPo0.05 vs. cisplatin group.
Table shows body weight in the different study groups at the beginning and end of
the study. Results are expressed as mean±s.e.m.; n=7–8 animals per group.
Table 2 | Effects of cilastatin on cisplatin-induced nephrotoxicity in rats
Groups SCreat (mg/dl) BUN (mg/dl) GFR (ml/min/100g) UVol (ml/24 h) UProt (mg/24h) FENaþ (%) FEH2O (%)
Control 0.33±0.02 33.50±3.03 0.83±0.06 15.17±1.38 26.10±3.76 0.47±0.04 0.46±0.03
Control+cil 0.33±0.02 30.20±2.48 0.72±0.06 14.17±2.34 27.72±2.65 0.53±0.04 0.53±0.05
Cisplatin 1.10±0.06a 80.00±5.20a 0.20±0.02a 29.14±2.04a 44.90±5.62a 1.65±0.17a 4.64±0.37a
Cisplatin+cil 0.67±0.08a,b 50.00±4.12a,b 0.38±0.04a,c 17.50±3.70b 29.00±1.57b 0.76±0.08b,d 1.61±0.41b,e
Abbreviations: BUN, blood urea nitrogen; cil, cilastatin; FE, fractional excretion; GFR, glomerular filtration rate; SCreat, serum creatinine; UProt, urinary protein;
UVol, urinary volume.
aPo0.005 vs. control and controlþ cil.
bPo0.005 vs. cisplatin.
cPo0.05 vs. cisplatin.
dPo0.05 vs. control group.
ePo0.05 vs. control and control+cil.
Results are expressed as mean±s.e.m.; n¼ 7–8 animals per group.
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assessed both by immunohistochemistry and by western
blot of the renal cortex (Figure 3f and h). Renal cortex
procaspase-9 and cleaved caspase-9 were also markedly
increased after administration of cisplatin; both were also
attenuated by cilastatin (Figure 4).
Expression of Bax/Bcl-2 proteins. Apoptotic Bax and anti-
apoptotic Bcl-2 expressions were measured in the renal
cortex. Bax increased significantly in the cisplatin-treated
group compared with the control group, and this increase
was significantly diminished by cilastatin (Figure 5a and b).
No changes were observed with respect to the controls in Bcl-
2 protein levels in cilastatin-treated cisplatin-injected rats or
cisplatin-treated rats (Figure 5a and c). The ratio of Bax to
Bcl-2 was calculated as an index of the susceptibility of the
cells to apoptosis: an increased ratio indicates predisposition
to apoptosis. This was significantly higher in the kidneys of
cisplatin-treated rats than in control rats. Cilastatin reversed
the increase in the Bax/Bcl-2 ratio in cisplatin-injected rats
(Figure 5d).
The extrinsic pathway of apoptosis. We investigated
whether cilastatin modulated the Fas/Fas ligand (FasL) system
and activator caspase-8. Cisplatin increased renal cortex Fas,
FasL, and caspase-8 levels compared with untreated animals
(Figure 6). Cilastatin significantly decreased protein expres-
sion of Fas, FasL, and caspase-8 (Figure 6). Cilastatin alone
had no effect on any of the above-mentioned apoptotic
variables.
Effect of cilastatin on cisplatin-induced OS
Evidence of OS was found both in urine and in the kidneys of
cisplatin-treated rats.
Cilastatin blunts cisplatin-induced increased ROS formation
and enhances antioxidant defenses. OS results from the
imbalance between ROS generation and destruction. To
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Figure 1 |Cilastatin (cil) improves renal histology in cisplatin-injected rats. Representative images of the renal pathology
(hematoxylin–eosin staining, magnification  20) on day 5 after administration of cisplatin. (a) Control rats, (b, e) cisplatin (renal cortex and
medulla, respectively), (c) controlþ cilastatin, and (d, f) cisplatinþ cilastatin (renal cortex and medulla, respectively). Control groups show
normal renal structure; cisplatin-injected kidneys show marked injury with sloughing of tubular epithelial cells, loss of brush border, dilation
of tubules, vacuolization, and intratubular cast formation (arrows). These changes were significantly reduced by treatment with cilastatin,
with the kidneys showing almost normal morphology; bar¼ 100 mm. (g, h) Details of renal tubules of cisplatin and cisplatinþ cilastatin
groups, respectively (magnification  60), showing the presence of vacuolization (arrows). Cilastatin completely reduced the damage;
bar¼ 25mm. (i) Semiquantitative renal injury score (see Materials and Methods section). Results are expressed as mean±s.e.m.; n¼ 7–8
animals per group.*Po0.01 compared with other groups.
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evaluate the role of cilastatin in countering cisplatin-
induced OS, we measured ROS and antioxidant capacity
in urine. Urine from cisplatin-treated rats contained a
larger amount of hydrogen peroxide than the control
group, and this was decreased by cilastatin (Figure 7a).
Furthermore, cisplatin significantly decreased antioxidant
capacity in urine, which was partially improved by cilastatin
(Figure 7b).
Catalase (an antioxidant enzyme) expression was de-
creased in renal cortex of cisplatin-treated rats. Cilastatin
restored catalase expression (Figure 7c and d).
Heat shock protein 27 (HSP 27) protects cells from
apoptosis and enhances antioxidant defenses. Expression of
HSP 27 was markedly greater in cisplatin-treated rats than in
controls. Cilastatin significantly decreased kidney HSP 27
levels (Figure 7e and f).
Cilastatin reduces cisplatin-induced lipid peroxidation.
4-Hydroxy-2-nonenal and malondialdehyde (MDA) are pro-
ducts of fatty acid oxidation. Cisplatin enhanced 4-hydroxy-2-
nonenal staining (Figure 8a–e) and increased MDA levels
(Figure 8f–h) in the kidneys when compared with the controls.
This was completely prevented by cilastatin.
Cilastatin alone did not modify these variables compared
with the control group.
Pharmacokinetics
Cisplatin pharmacokinetics was studied following a single
intraperitoneal (i.p.) injection in the presence or absence of
cilastatin (Table 3 and Figure 9c). The area under the curve
(AUC) of serum cisplatin was not significantly different between
animals treated with or without cilastatin. Cilastatin decreased
the cisplatin elimination rate constant and increased Pt half-life
(t1/2) (Table 3). Although maximum Pt concentration (Cmax)
was attained at similar time points in both the cases, Cmax was
slightly lower in the cilastatin-treated group (Po0.05).
Cilastatin reduces incorporation of cisplatin in the renal
cortex
As previously described in RPTECs exposed to cisplatin,17
in vivo cilastatin also decreased renal cortical tissue Pt in rats
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Figure 2 |Cilastatin (cil) decreases tubular cell apoptosis in cisplatin-injected rats. Photomicrographs of terminal deoxynucleotidyl
transferase (TdT)-mediated dUTP nick end labeling (TUNEL) staining in the kidneys. (a) Control rats, (b) controlþ cilastatin, (c) cisplatin, and
(d) cisplatinþ cilastatin. Green fluorescent staining indicates TUNEL-positive nuclei, and blue staining (4,6-diamidino-2-phenylindole (DAPI))
represents all nuclei in the sample (magnification  20). (e) Quantitative analysis of TUNEL-positive cells. Results are expressed as
mean±s.e.m.; n¼ 7–8 animals per group. *Pp0.001 vs. all other groups.
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following administration of cisplatin (Figure 9a). Decreased
cortical Pt probably reflects the specific lower accumulation
of Pt in RPTECs, because no differences were observed in
medullary Pt accumulation. Indeed, medullary Pt was lower
than cortical Pt content in both groups of rats.
There was no qualitative change in the chromatographic
profile of Pt-containing proteins, irrespective of whether rats
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Figure 3 |Cilastatin (cil) diminishes cisplatin-induced caspase-3 expression. Localization of active cleaved caspase-3 in kidney sections.
(a) Control rats; (b, e) cisplatin; (c) controlþ cilastatin; and (d) cisplatinþ cilastatin. Note that renal tubules are the main site of caspase-3
activation in cisplatin-treated animals (arrows, magnification  20). Cilastatin significantly reduced expression of active caspase-3 induced
by cisplatin. (f) Representative western blots of procaspase-3 and active cleaved caspase-3 in renal cortex. (g, h) Densitometric analysis of
western blots of procaspase-3 and active cleaved caspase-3, respectively. Data are expressed as mean±s.e.m.; n¼ 7–8 animals per group.
*Pp0.01 vs. all other groups. a.u., arbitrary units.
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Figure 4 |Cilastatin (cil) prevents caspase-9 (casp)
upregulation in cisplatin-injected rats. (a) Representative
photomicrographs of western blots of procaspase-9 and
active cleaved (Cleav) caspase-9 in renal cortex. (b) Densitometric
analysis of procaspase-9 and active caspase-9 levels on
western blots. Data are expressed as mean±s.e.m.; n¼ 7–8
animals per group. *Pp0.05 vs. all other groups. a.u.,
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by cisplatin. (a) Representative photomicrographs of western
blot of Bax and Bcl-2 in renal cortex. (b–d) Densitometric analysis
of Bax, Bcl-2, and Bax/Bcl-2 ratio levels, respectively, on western
blots. Data are expressed as mean±s.e.m.; n¼ 7–8 animals per
group. *Pp0.01 vs. all other groups; wP¼ 0.046 vs. control;
#Po0.05 vs. all other groups. a.u., arbitrary units.
656 Kidney International (2012) 82, 652–663
or ig ina l a r t i c l e B Humanes et al.: Cilastatin reduces cisplatin-induced renal damage
were treated with cilastatin (Figure 9b). Pt-bound proteins
were observed within the whole separation range (3–70 kDa),
and the most intense peaks corresponded to species around
20 and 65 kDa. Moreover, no significant peaks were observed
for intact cisplatin or the intracellular monoaquo complex,
indicating that all Pt is bound to biomolecules.
Effects of cilastatin on cancer cells
To evaluate if cilastatin reduction in cisplatin nephrotoxicity
was specific for the kidney, we looked for potential reductions
in chemotherapeutic efficacy of cisplatin on different tumor
cell lines. In Figure 10, the effect of cisplatin on the apoptosis
of HeLa cells is depicted. Increasing doses of cisplatin caused a
dose-dependent loss of cells, a rise in the percentage of cells
with apoptosis-like nuclei (Figure 10a and b) and caspase-3
activation (Figure 10c). Cilastatin was unable to revert any of
these effects. DHP-I activity was measured in HeLa cells and
compared with cultured RPTECs (Figure 10d). The specific
DHP-I activity was very low in HeLa cells and was not
inhibited by cilastatin. However, in the presence of cilastatin
we observed a 24% reduction in the intracellular content of
cisplatin in HeLa cells (Figure 10e). This reduction apparently
was neither related to the protective properties of cilastatin
nor its ability to inhibit DHP-I.
Moreover, cisplatin reduced cell survival in cervical cancer
(Figure 11a), colon cancer (Figure 11b and f), breast cancer
(Figure 11c and e), and bladder cancer (Figure 11d) derived
cell lines, and this effect was time dependent. Cilastatin did not
protect any of these cells from cisplatin-induced cell death.
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Figure 7 |Cilastatin (cil) decreases cisplatin-induced oxidative
stress. (a) Urine hydrogen peroxide (H2O2) production and
(b) antioxidant capacity in urine were measured in rats using
specific kits. H2O2 concentration was higher in cisplatin-injected
rats than in cisplatin-injected rats treated with cilastatin
and control rats. In contrast, antioxidant capacity had the
opposite effect. (c, d) Representative photomicrographs of
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analysis, respectively. (e, f) Representative photomicrographs of
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respectively. All results are expressed as mean±s.e.m.; n¼ 7–8
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Kidney International (2012) 82, 652–663 657
B Humanes et al.: Cilastatin reduces cisplatin-induced renal damage o r ig ina l a r t i c l e
DISCUSSION
Nephrotoxicity is the main adverse effect of cisplatin,
primarily induced by accumulation of Pt in kidney cells,20
followed by apoptosis, and, in a minor proportion,
necrosis.6,17,21 Renal tubules are the main targets in
cisplatin-induced nephrotoxicity,6 and both intrinsic and
extrinsic pathways have been involved in proximal tubular
cell apoptosis.5,6,8,17,22,23 OS and inflammation have also
been involved in critical roles.5,6,21,24
In several in vitro models of toxicity on RPTECs, cilastatin
incubation resulted in marked protection.17–19 As only
RPTECs have brush border-bound renal DHP-I, our results
suggested that protection would be specific for RPTECs, but
we had no evidences on the clinical relevance of these
findings in an animal model. Here, we show that cilastatin
significantly protects against cisplatin-induced nephrotoxi-
city and attenuates cisplatin-induced apoptosis and OS
in vivo, without affecting its antitumor activity.
The rat model of acute cisplatin renal dysfunction induced
by a single dose of drug was chosen because of its
reproducibility and similarity to clinical situations.3,16,25–27
A single injection of cisplatin in rats causes tubular cell
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Table 3 | Pharmacokinetic parameters estimate for cisplatin and cisplatin plus cilastatin in rats
Parameters Unit Cisplatin Cisplatin+cilastatin P-value
Cmax mg/l 3335±181 2300±56 o0.05
tmax Min 15±0 15±0 NS
t1/2 Min 135±15 279±27 o0.05
Elimination ratio constant mg/ml/min 5.23±0.57 2.50±0.24 o0.05
AUC (mg min)/ml 361.0±11.1 402.7±6.2 NS
Abbreviations: AUC, area under the curve; Cmax, maximum platinum concentration; NS, nonsignificant; tmax, time to obtain Cmax; t1/2, half-life of platinum. The pharmacokinetic
parameters were calculated using Microsoft Excel fitted with pharmacokinetic functions written for Excel (see Materials and Methods for details).
Results are expressed as mean±s.e.m.; n=4 animals per group.
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injury, decreased glomerular filtration rate, and increased
serum creatinine, blood urea nitrogen, and fractional
excretion of sodium. The reduction in body weight following
cisplatin administration was caused by polyuria resulting
from tubular injury, which in turn leads to dehydration,
although gastrointestinal toxicity may also contribute.28,29
Cilastatin significantly improved—in part or completely—all
these manifestations of cisplatin-induced nephrotoxicity.
Histopathology score of damage were also much improved.
Our results show that the protection afforded in vivo by
cilastatin is associated with reversal of cisplatin-induced
apoptosis and changes in apoptotic regulatory protein levels
or state of activation. Specifically, cisplatin increased levels of
renal native and glycosylated Fas, FasL, Bax, and cleaved
caspase-3, -8, and -9, all of which were reversed by cilastatin.
Cisplatin did not modify Bcl-2, finding that is consistent with
previous observations.3,12,30
Cisplatin generates ROS and inhibits the activity of anti-
oxidant enzymes in renal tissue.11,13,14,16,22 In our study, we
also showed increased hydrogen peroxide levels and marked
deterioration of the endogenous antioxidant profile in the
kidneys and urine of cisplatin-treated rats. Administration
of cilastatin improved both findings. Lipid peroxidation
via ROS generation is usually associated with cisplatin-
induced nephrotoxicity.16,25,30,31 In this regard, cilastatin also
decreased the amount of kidney MDA and 4-hydroxy-2-
nonenal observed in cisplatin-treated rats. Similar results
were obtained when antioxidants such as curcumin, resver-
atrol, lycopene, and others were used in experimental
cisplatin-induced nephrotoxicity.13,16,25,29 Unfortunately,
many of the studies cited above did not analyze whether
these approaches would limit the tumoricidal efficacy of
cisplatin, limiting its potential clinical use. Very recently, it
has been reported that quercitin prevents the nephrotoxic
effect of cisplatin without affecting its antitumor activity in
rats.32 Pabla et al.33 have also shown that the inhibition of
protein kinase Cd enhances the chemotherapeutic effect of
cisplatin in several tumor models while protecting kidneys
from nephrotoxicity.
HSPs may also have an important role in protecting cells
from injury, and their expression correlates strongly with the
degree of OS in rat proximal tubules.30,34 In fact, HSP 70
protects against cisplatin-induced cytotoxicity in tubular
cells.35 The increased levels of HSP 60 and 90 observed after
treatment with cisplatin are decreased by antioxidants that
ameliorate cisplatin-induced acute renal failure.30,36 The
most plausible explanation is that cells with decreased levels
of injury fail to upregulate compensatory cell protection
mechanisms, because these are no longer needed. Consistent
with these observations, cisplatin increased HSP 27, an anti-
apoptotic molecule that inhibits Fas-induced apoptosis and
modulates ROS and glutathione levels.37 Cilastatin restored
normal levels of HSP 27, and we hypothesize that this is a
consequence of its cytoprotective effect.
Pharmacokinetics showed similar AUC for cisplatin with
or without cilastatin. However, the cisplatin elimination rate
constant was slightly slower in the presence of cilastatin.
As long as creatinine clearance was better preserved with
cilastatin, changes in excretion suggested a higher reabsorp-
tion or a reduced secretion. From our previous experiences,
we knew cilastatin interfered with cisplatin accumulation
into RPTECs.17 We did not know if this effect was relevant to
nephroprotection, specific for proximal tubule or related to
the inhibition of DHP-I. In our in vivo model, 5 days after
cisplatin injection we were able to recover Pt from kidney
homogenates. Simultaneous treatment with cilastatin did not
make any difference with cisplatin content in medulla, but
reduced the cisplatin recovered from renal cortex by 22%. We
have confirmed these findings by laser ablation inductively
coupled plasma mass spectrometry on renal slices obtained
from our model: kidneys obtained from animals treated with
cilastatin and cisplatin displayed lower content of Pt38 and
copper in the cortex, but not in medulla, where levels of both
metals were similar to those observed in animals treated with
cisplatin alone (data not shown). Cilastatin is able to inhibit
certain basolateral organic anion transporters in proximal
tubule cells.39–41 But reduction in intracellular content of Pt
and copper in renal cortex, even if modest in quantity,
suggest that it may also inhibit other basolateral transporters
like Ctr1, involved in Pt and copper basolateral transport in
proximal tubules.42
Interestingly, our studies on cancer-derived HeLa cell lines
displayed very low levels of specific DHP-I activity, and
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Figure 9 | Effect of cilastatin (cil) on platinum (Pt), speciation
analysis, and pharmacokinetics in cisplatin-injected rats. (a) Pt
concentration in the renal cortex and medulla of the animals 5
days after cisplatin administration. Cilastatin reduces renal cortex
Pt accumulation by 22%. Data are expressed as mean±s.e.m.;
n¼ 7–8 animals per group. *Po0.005 vs. cisplatin group. (b) Size
exclusion/inductively coupled plasma mass spectrometry (195Pt
signal) chromatograms from renal cortex of cisplatin-injected rats
and cilastatin-treated cisplatin-injected rats. Cilastatin reduces the
height of detected peaks without changing their retention times,
distribution, or relative proportion. (c) Serum cisplatin
pharmacokinetic profile followed for 4 h after intraperitoneal
injection of cisplatin with or without coadministration of cilastatin
(n¼ 4). Effect of cilastatin kinetic parameters are displayed in
Table 3 and discussed in the text. Prot, protein.
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cilastatin did not modify either DHP-I activity or cisplatin-
induced cell death. Similarly, several cancer cell lines were not
protected by cilastatin against the cytotoxic effects of
cisplatin. However, we observed an inhibition of 24% in
the intracellular content of cisplatin on HeLa cells treated
with cilastatin. These findings complete our previous
observations about the effect of cilastatin on tumor-derived
cells.17 Table 4 compares the inhibitory effects of cilastatin on
different parameters of RPTECs or HeLa cells treated with
cisplatin.
Cilastatin causes a modest inhibition of Pt cell transport
that is not specific to kidney cells. This reduction in Pt
intracellular content is not related with DHP-I presence or
activity, and does not seem to have a major role on the
intensity of induced apoptosis. On the other hand, cilastatin
protection and DHP-I inhibition by cilastatin seem to be
specifically restricted to proximal tubule cells.
Fas-mediated cell death requires the clustering of the
Fas receptor in lipid rafts.43,44 Exposure of human colon
carcinoma cells to cisplatin induces formation of Fas
aggregates and their redistribution into plasma membrane
lipid rafts, together with the intracellular signaling molecules,
Fas-associated protein with death domain and procaspase-8.45
Furthermore, disruption of rafts abolishes the initiation of Fas
death signaling in thymocytes and Jurkat cells.46,47 We have
recently observed that binding of cilastatin to proximal tubule
renal DHP-I inhibits internalization of brush border lipid
rafts.17,19 In the presence of cisplatin, cilastatin inhibits
internalization of Fas–FasL bound to cell membrane lipid
rafts.17 Here, we have observed that levels of Fas and FasL are
decreased when cilastatin is present, and it could be related to
reductions in caspase-8, -3, and apoptosis.
In summary, this study provides evidence that cilastatin
reduces in vivo cisplatin nephrotoxicity by interference with
extrinsic apoptotic mediators. Cilastatin does not interfere
with the cytotoxic effects of cisplatin on tumor cell targets (as
long as they do not have renal DHP-I) and does not modify
the cisplatin AUC. Therefore, cilastatin has the potential to
preserve renal function in cisplatin-treated cancer patients
without compromising the efficacy of anticancer therapy.
Vehicle
0
a
10
30
Cisplatin
(μmol/l)
Cilastatin 35
0 10 30Cisplatin
(μmol/l)
Ca
sp
as
e-
3 
ac
tiv
ity
(nm
ole
 pN
A/
μg
 p
ro
te
in
)
20
16
12
8
4
0
20
60
100
140
60
40
20
0
*
#
*180
0 30
25
15
Ap
op
to
tic
 n
uc
le
i (%
)
5
0
RPTECs HeLa cells
101 30Cisplatin
(μmol/l)
Cisplatin
(μmol/l)
H
eL
a 
ce
ll 
Pt
 c
on
te
nt
(μg
 P
t/g
 p
ro
t)
G
ly-
ph
e 
di
pe
pt
id
as
e 
ac
tiv
ity
(m
U/
mg
 pr
ot 
×
 
10
–
3 )
b
c
d e
Vehicle
Cilastatin
Vehicle
Cilastatin
Vehicle
Cilastatin
Vehicle
Cilastatin
Figure 10 | Effect of cilastatin on cisplatin-induced cell death in HeLa cancer cells. HeLa cells were treated with cisplatin alone (1, 10,
and 30mmol/l) or in combination with 200 mg/ml cilastatin for 24 h. (a) Nuclear staining with 4,6-diamidino-2-phenylindole (DAPI). Cells were
stained with DAPI to study apoptotic-like nuclear morphology. Arrows point to fragmented apoptotic nuclei. Bar¼ 20mm. (b) Quantitative
approach to the images presented in a. (c) Activation of caspase-3. (d) Dehydropeptidase I (DHP-I)–specific activity in cultured renal
proximal tubular epithelial cells (RPTECs) and HeLa cells. Activity was determined by the hydrolysis of 1 mmol/l gly-phe-p-nitroanilide in the
presence or absence of 200 mg/ml cilastatin. Data are expressed as mean±s.e.m. of at least three separate experiments and show that
cilastatin does not interfere with the cytotoxic effect of cisplatin on tumor cells; *Po0.0005 vs. same data without cilastatin. (e) Platinum (Pt)
was measured in HeLa-soluble fractions using quadrupole inductively coupled plasma mass spectrometry. Values were expressed as the
mean±s.e.m. of Pt concentration, expressed in micrograms of Pt per gram of protein (prot; n¼ 4 different experiments). Analysis of
variance model, Po0.0001; *cilastatin effect, Pp0.05; #dose effect, Pp0.05.
660 Kidney International (2012) 82, 652–663
or ig ina l a r t i c l e B Humanes et al.: Cilastatin reduces cisplatin-induced renal damage
MATERIALS AND METHODS
Drugs
Cisplatin was obtained from Pharmacia (Barcelona, Spain). Crystal-
line cilastatin was provided by Merck Sharp and Dohme SA
(Madrid, Spain). Both cisplatin and cilastatin were dissolved in
normal 0.9% saline (vehicle).
Proximal tubular primary cell culture and cancer cell line
cultures
Porcine RPTECs were obtained as described previously17,19 (further
detail in Supplementary Information).
Breast (MDA-MB-231 and SKBR3), colon (LoVo and HCT-116),
and bladder (253J) cancer cells lines were generously provided by
Francisco del Real (CNIO, Madrid, Spain). Cells were cultured
equally that HeLa cervical tumor cells17 plus 1% sodium pyruvate.
Cancer cells viability was measured using MTT ((3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay as
previously described.17
Cellular cisplatin uptake and cell death studies in HeLa cells
HeLa cells incubated for 24 h with increasing concentrations of
cisplatin in the presence or absence of cilastatin (200 mg/ml) were
used to measure cell death (apoptotic nuclei and caspase-3 activity)
and uptake of cisplatin as previously described.17 Further details are
found in Supplementary Information.
DHP-I activity assay
DHP-I activity assay was realized in RPTECs and HeLa cells as
previously described.17
Animals and experimental protocols
Studies were performed on 7-week-old male Wistar rats weighing
250–270 g (Criffa, Barcelona, Spain). The animals were housed
under controlled light (12-h light–dark cycle), temperature,
and humidity with free access to food and water. Rats were
weighed at the beginning of the experiment and just before killing.
The study was approved by the Institutional Board for Animal
Experiments. Animals were handled at all times according to the
applicable legal regulations in RD 1201/2005, of 10 October, on the
protection of animals used for experimentation and other scientific
purposes.
The study population comprised 30 animals, which were
randomized into four groups: untreated control rats (n¼ 7);
cilastatin-treated rats (n¼ 7); cisplatin-injected rats (n¼ 8); and
cilastatin-treated cisplatin-injected rats (n¼ 8). Cisplatin (5mg/kg)
or its vehicle was administered by a single i.p. injection to rats in the
same manner and volume (1ml/100 g). Cilastatin was injected i.p. at
75mg/kg twice daily from the day of cisplatin administration and
until the day of killing. The first dose of cilastatin was administered
just before administration of cisplatin. Cilastatin was substituted
by vehicle (0.25ml/100 g) in the other groups. The dose and
administration period of cisplatin were selected based on the proven
effectiveness of the drug in inducing nephrotoxicity.3,12,16,25,26 The
dose of cilastatin was selected from pilot studies based on previous
experience,48,49 which showed that imipenem/cilastatin reduced
cyclosporin-induced nephrotoxicity. One day before the rats were
killed, the urine of each animal was collected over a 24-h period and
the volume measured. On the fifth day after the cisplatin or saline
injection, all animals were anesthetized with ketamine (10mg/kg)
and diazepam (4mg/kg) and killed. Blood and kidney samples were
collected and stored for the different studies (further detail in
Supplementary Information).
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Figure 11 | Effect of cilastatin on the antitumor efficacy of
cisplatin. (a) HeLa, (b) LoVo, (c) SK BR3, (d) 253J, (e) MDA-MB-231,
and (f) HCT-116 cancer cells were treated with cisplatin (cispla)
alone (30 mmol/l) or in combination with 200mg/ml cilastatin (cil)
at 24 and 48 h and cell viability was determined by MTT ((3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay.
Cells incubated in the absence of cisplatin and cilastatin were
used as 100%. Data are expressed as mean±s.e.m. of four
separate experiments and show that cilastatin does not interfere
with the cytotoxic effect of cisplatin on tumor cells. Analysis of
variance model, Po0.0005. Factors: cisplatin effect, Po0.0005;
cilastatin effect, nonsignificant (NS); time effect, Po0.0005; cell
type effect, Po0.0005. Interactions: cell type cisplatin effect,
Po0.0005; cisplatin cilastatin effect, NS; cilastatin time, NS.
Table 4 | Comparison of cytotoxicity inhibition by cilastatin
between renal proximal tubular epithelial cells and HeLa
cancer cells
Parameter
Cultured renal proximal
tubular epithelial cells
(%)
Cultured
HeLa cells
(%)
Intracellular platinum 23.8a17 24.4a
DNA-bound platinum (detached
cells)
43.7a17 0.0b17
Apoptosis (nuclear damage)c 63.8a17 0.0b17
Apoptosis (mitochondrial
damage)d
20.6a17 4.4b17
Caspase-3 activity 32.7a17 5.4b
aInhibition percentage different from 0, Pp0.05.
bInhibition statistically nonsignificant.
cNuclear damage was estimated from 4,6-diamidino-2-phenylindole staining data.
dMitochondrial damage was estimated from MTT ((3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assay data.
Table shows the effect of cilastatin in reducing parameters previously elevated by
cisplatin treatment in both cell types. Results are expressed as % of reduction.
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Renal function monitoring
Serum creatinine, blood urea nitrogen levels, and other parameters
were measured using the Dimension RxL autoanalyzer (Dade-
Behring, Siemens, Eschborn, Germany). The glomerular filtration
rate was calculated using the creatinine clearance rate. Total protein
in urine was measured using sulfosalicylic acid method.50
Renal histopathological studies
For light microscopy, paraffin-embedded renal sections (4-mm
thick) were stained with hematoxylin–eosin (Sigma-Aldrich, St
Louis, MO). The kidney injury score was calculated using a
previously described semiquantitative index.51
Immunohistochemistry
Immunohistochemistry was carried out as described previously.51 The
primary antibodies used are found in Supplementary Information.
Western blotting analysis
Western blotting was performed as described previously.17,50 The
primary antibodies used are found in Supplementary Information.
In situ detection of apoptosis
DNA fragmentation as an index of apoptosis was detected by
terminal deoxynucleotidyl transferase-mediated dUTP nick end
labeling in paraffin-embedded kidney tissue sections using a
Fluorescein FragEL DNA Fragmentation Detection Kit (Calbiochem,
San Diego, CA) following the manufacturer’s protocol (Supplemen-
tary Information).
Assessment of lipid peroxidation
MDA in renal homogenate was measured by the method of
Recknagel et al.52 Details are found in Supplementary Information.
Urine levels of antioxidant and hydrogen peroxide
Urine levels of antioxidant and hydrogen peroxide were measured
using the commercially available Antioxidant Assay Kit (Cayman
Chemical, Ann Arbor, MI) and Colorimetric Hydrogen Peroxide Kit
(Assay Designs, Stressgen, Ann Arbor, MI), respectively, according
to the manufacturer’s protocol.
Renal Pt determination and speciation analysis
Renal tissue was pulverized and digested with lysis buffer (further
detail in Supplementary Information). The supernatant was analyzed
for total protein content and cisplatin (as Pt) using inductively
coupled plasma mass spectrometry as previously described.17
Pt-biomolecule speciation was analyzed using high-performance
liquid chromatography/inductively coupled plasma mass spectro-
metry as described elsewhere.17
Pharmacokinetics
A catheter was inserted into the tail vein under anesthesia (ketamine
50mg/ml and xylacine 2%). Rats were given a single i.p. injection of
cisplatin (5mg/kg, n¼ 4), or cisplatin plus cilastatin (75mg/kg, i.p.,
n¼ 4). Cilastatin was substituted by vehicle in the cisplatin group.
Blood samples were collected at 0, 15, 30, 60, 120, and 240min after
injections via the catheter. Total Pt was measured in serum aliquots
by inductively coupled plasma mass spectrometry. AUC, CMax, time
to maximal Pt concentration (tMax), elimination rate constant, and
t1/2 were estimated for each animal. The program used was
Microsoft Excel fitted with pharmacokinetics functions written for
Excel by Joel I Usansky, Atul Desai, and Diane Tang Liu (Allergan,
Irvine, CA); (http://www.boomer.org/).
Statistical analysis
Quantitative variables were summarized as the mean±s.e.m.
Equality of variances was tested with Levene’s text. Normally
distributed continuous variables with equal variances were analyzed
with analysis of variance. If variances were not equal, the
Kruskal–Wallis test was performed. Differences were considered
statistically significant for bilateral a-values o0.05. Tests were
performed using SPSS 11.5 software package (SPSS, Chicago, IL).
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